Tirzepatide is a dual GIP and GLP-1 receptor agonist supplied as an injectable formulation. It is studied for its role in activating both GIP and GLP-1 receptor signaling and the downstream metabolic and appetite-related pathways associated with these receptors.

This formulation is used in controlled laboratory workflows and in-vitro systems examining GIP and GLP-1 receptor activity, appetite-related hormone signaling, and glucose-regulation mechanisms. It is applied in structured research models characterizing receptor activity and downstream pathway interactions.

Tirzepatide supports analytical studies and cell-based models involving dual GIP/GLP-1 receptor agonism, satiety signaling, insulin- and glucose-related pathways, and broader metabolic efficiency. It is relevant for pathway characterization and assay development focused on endocrine and metabolic cross-talk within controlled study frameworks.

Tirzepatide is suited for researchers and investigators exploring dual-incretin receptor signaling, metabolic regulation, and energy-balance mechanisms within controlled study frameworks.